Belzupacap sarotalocan is under clinical development by Aura Biosciences and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Belzupacap sarotalocan’s likelihood of approval (LoA) and phase transition for Choroidal Disease took place on 06 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Belzupacap sarotalocan Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Belzupacap sarotalocan overview

AU-011 is under development for the treatment of ocular melanoma (melanomas of the iris and the ciliary body), uveal and choroidal melanoma. It is administered as an intravitreal, suprachoroidal, intratumoral and intramural route. The therapeutic candidate is developed based on Nanosmart technology. The drug candidate is a VDC (virus like drug conjugate).

Aura Biosciences overview

Aura Biosciences is working on a novel class of oncology targeted therapeutics that will provide considerable therapeutic benefit to a variety of cancer indications with a high unmet need. The company is headquartered in United States.

Quick View Belzupacap sarotalocan LOA Data

Report Segments
  • Innovator
Drug Name
  • Belzupacap sarotalocan
Administration Pathway
  • Intraocular
  • Intratumor
  • Intravitreal
  • Parenteral
Therapeutic Areas
  • Oncology
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.